NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 16 min ago

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

Tue, 2024-04-23 11:21
Funding Opportunity PA-24-191 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ().

Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)

Tue, 2024-04-23 11:20
Funding Opportunity PA-24-192 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

Tue, 2024-04-23 11:20
Funding Opportunity PA-24-190 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)

Tue, 2024-04-23 11:19
Funding Opportunity RFA-AI-24-017 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research that 1) defines associations between variations in human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, 2) elucidates mechanisms underlying these associations with the goal of advancing therapeutic opportunities, and/or 3) validates association data in order to improve the predictive power of clinical disease screening.

Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)

Tue, 2024-04-23 11:18
Funding Opportunity RFA-DK-25-010 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research. Information about the currently funded CF Research and Translation Centers may be found at: https://www.niddk.nih.gov/research-funding/research-programs/cystic-fibrosis-research-translation-centers or https://www.cysticfibrosiscenters.org/.

Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)

Tue, 2024-04-23 04:04
Funding Opportunity RFA-CA-24-023 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This NOFO seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Tue, 2024-04-23 04:01
Funding Opportunity RFA-CA-24-022 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Findings of Research Misconduct

Fri, 2024-04-19 11:57
Notice NOT-OD-24-108 from the NIH Guide for Grants and Contracts

Notice to Remove Risk Assessment Questionnaire Requirement for RFA-OH-22-002: Centers for Agricultural Safety and Health (U54)

Fri, 2024-04-19 11:55
Notice NOT-OH-24-011 from the NIH Guide for Grants and Contracts

Request for Information (RFI) on Data Management, Sharing, and Secondary Data Use Challenges and Opportunities

Fri, 2024-04-19 11:54
Notice NOT-AG-24-013 from the NIH Guide for Grants and Contracts

Request for Information (RFI): Input on NIAID Immunology Knowledge Management

Fri, 2024-04-19 11:51
Notice NOT-AI-24-036 from the NIH Guide for Grants and Contracts

The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)

Fri, 2024-04-19 11:50
Funding Opportunity PAR-24-153 from the NIH Guide for Grants and Contracts. The purpose of the Worta McCaskill-Stevens K12 funding opportunity is to support institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers in community oncology or cancer prevention, and to facilitate their transition to more advanced support mechanisms or independent research funding (e.g., K08, R03, R21, R01). The NOFO will allow the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; or proposing a separate ancillary study to an existing prevention, screening or control clinical trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of underserved or underrepresented communities in cancer clinical research, as part of their research and career development.

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)

Fri, 2024-04-19 11:46
Funding Opportunity PAR-24-110 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce health disparities for other health outcomes among populations that experience health disparities.

Request for Information (RFI): Inviting Input Regarding NIDCDs Research Directions in Global Health

Fri, 2024-04-19 02:06
Notice NOT-DC-24-027 from the NIH Guide for Grants and Contracts

NIMH Funding Priorities for Applications Supporting Exceptionally Well-Funded Investigators

Fri, 2024-04-19 02:05
Notice NOT-MH-24-230 from the NIH Guide for Grants and Contracts

NIH Entrepreneurship Boot Camp for pre-SBIR/STTR Innovators

Fri, 2024-04-19 02:03
Notice NOT-OD-24-103 from the NIH Guide for Grants and Contracts

Pages